[12] Patent
[11] Patent No.:GC0007607  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126161
Date of the Decision to Grant the Patent:18/Apr/2018

[21] Application No.:GC 2010-17415

[22] Filing Date:21/12/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
CN
22/12/2009
19/11/2010
61/288,992
PCT/CN2010/078927

[72] Inventors:1- Joerg Berghausen،2- Nicole Buschmann،3- Pascal Furet،4- Francois Gessier،5- Joanna Hergovich Lisztwan،6- Philipp Holzer،7- Edgar Jacoby،8- Joerg Kallen،9- Keiichi Masuya،10- Carole Pissot soldermann،11- Haixia Ren،12- Stefan Stutz

[73] Owner: Novartis AG, Lichtstrasse 35, Basel 4056, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/495; A61P3 5/00; C07D 217/24, 401/04, 401/10, 401/12, 401/14, 405/04, 405/12, 405/14, 409/12, 413/10, 413/12, 413/14, 417/12 (2006.01)

[56] Cited Documents:

-WO 2008034039 A2 (NEXUSPHARMA INC [US]; WEBER LUTZ [DE]; KHAZAK VLADIMIR [US]; ROSS GUNT) 20 March 2008
-WO 03095625 A2 (DIMENSIONAL PHARM INC [US]; KOBLISH HOLLY K [US]; MANTHEY CARL L [US];) 20 November 2003
 
Examiner: PH. Sultana K. AlOudah

[54] SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES
[57] Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N-R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
No. of claims: 22     No. of figures: 2


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.